Domain III of the envelope protein as a dengue vaccine target (Q37682895)

22 August 2017

1 reference

title

Domain III of the envelope protein as a dengue vaccine target (English)

1 reference

22 August 2017

0 references

1 reference

Maria G Guzman

1

1 reference

22 August 2017

Lisset Hermida

2

1 reference

22 August 2017

Lidice Bernardo

3

1 reference

22 August 2017

Rosa Ramirez

4

1 reference

22 August 2017

Gerardo Guillén

5

1 reference

22 August 2017

1 February 2010

1 reference

Expert Review of Vaccines

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

2

1 reference

22 August 2017

137-147

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

22 August 2017

1 reference

Dengue: setting the global research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Research on dengue and dengue-like illness in East Asia and the Western Pacific during the First Half of the 20th century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Why dengue haemorrhagic fever in Cuba? 2. An integral analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Effect of age on outcome of secondary dengue 2 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human Fc RIA (CD64) or Fc RIIA (CD32)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Vaccines against dengue: a review of current candidate vaccines at advanced development stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Dengue vaccine: priorities and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Visualization of membrane protein domains by cryo-electron microscopy of dengue virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Structure of the dengue virus envelope protein after membrane fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Antigenic structure of flavivirus proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Localization of a neutralizing epitope on the envelope protein of dengue virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Passage of Dengue Virus Type 4 Vaccine Candidates in Fetal Rhesus Lung Cells Selects Heparin-Sensitive Variants That Result in Loss of Infectivity and Immunogenicity in Rhesus Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Dengue virus M protein contains a proapoptotic sequence referred to as ApoptoM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Production of dengue 2 envelope domain III in plant using TMV-based vector system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

P64k meningococcal protein as immunological carrier for weak immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.139

21 January 2018

Identifiers

DOI

10.1586/ERV.09.139

1 reference

22 August 2017

1 reference